Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Investing.com -- Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Hims & Hers Health has seen its stock drop 21% over the past month. The pullback is driven by regulatory updates from the FDA regarding tirzepatide injection shortages. Get Real-Time News and ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $25.90, demonstrating a +1.93% swing from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.16%.

HIMS), the leading health and wellness platform, today announced Dr. Jessica Shepherd is joining as the first Chief Medical Officer of Hers. As the company invests further in personalized ...

Cedar Grove Capital Management highlighted stocks like Hims & Hers Health ... From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand ...

Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...

The new $30 million Humboldt Park Health Wellness Center aims to improve preventive health services in an area with high ...

“Medical school is a whole new beast that the student has to learn how to tame, and things pick up very quickly, right from ...